試す 金 - 無料
Setting Bigger Targets For Next-Gen Vaccines
Bio Spectrum
|July 2024
New vaccine platform technologies could dramatically shorten the period from research to development, clinical trials, and vaccination. Reimagining R&D approaches in vaccine design and vaccine immunology may hold the key to significantly elevate the health impact of vaccines.
Experts worldwide are adopting novel research approaches in the molecular design of vaccines, and vaccine technology platforms. India is seeing increasing interdisciplinary research, and a rise in cutting-edge technological interventions in fundamental and translational research. The time is ripe for boosting out-of-the-box R&D approaches in vaccinology. Let's explore further.
The National Institute for Allergy and Infectious Diseases (NIAID), one of the 27 institutes and centres that make up the National Institutes of Health (NIH) of the US, referred to next-generation vaccines as those with enhanced breadth of protection to variants, improved durability, and enhanced ability to block infection/transmission relative to currently approved vaccines. The Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic, describes vaccine technology platforms as technologies that are essential for rapid responses to emerging viral threats.
Essentially, vaccine platform technologies are systems that use the same basic components as a backbone but can be adapted for use against different pathogens by inserting new genetic or protein sequences. Rational vaccine design, developed using suitable vaccine technology platforms, could thus present significant advantages in immunisation.
Creating such an unprecedented disease agnostic vaccine technology platform can empower the world to be ready for future pandemics. Studies have shown that next-generation vaccines can enable a higher spectrum of protection against multiple variants, increased durability, and minimal safety concerns due to side effects while increasing their immunogenicity.
Each vaccine's utility or efficiency is determined by its formulation, adjuvants, and mode of action.
このストーリーは、Bio Spectrum の July 2024 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー
Bio Spectrum
India & Australia develop precision nano-injection platform for breast cancer drug delivery
Researchers from the Indian Institute of Technology Madras (IIT-M), Monash University and Deakin University, Australia, have developed a cutting-edge nano-injection drug delivery platform that has the potential to make breast cancer treatment safer and more effective.
1 min
February 2026
Bio Spectrum
Agilent opens India Refurbishment Centre in Manesar
Agilent Technologies Inc., a global leader in life sciences, diagnostics, and applied chemical markets, has announced the inauguration of its India Refurbishment Centre at its LEED Platinum-certified facility in Manesar, Haryana.
1 min
February 2026
Bio Spectrum
Yashoda Medicity appoints Dr Rajinder Kumar as Unit Head, Department of Neurosurgery
Yashoda Medicity, one of the leading hospitals in the Delhi NCR, has appointed Prof. Dr Rajinder Kumar as Principal Director & Unit Head, Neurosurgery at the Yashoda Institute of Neurosciences.
1 min
February 2026
Bio Spectrum
Park Medi World buys KP Institute of Medical Sciences for Rs 245 Cr
Park Medi World Limited, North India's second largest chain of hospitals, has agreed to acquire KP Institute of Medical Sciences (KPIMS), in an all-cash transaction amounting to Rs 245 crore.
1 min
February 2026
Bio Spectrum
146 Biosimilars in 25 Years: India at Global Scale
Biosimilars are an important part of modern therapeutics and a central component of India's shift beyond a generics-led pharmaceutical model.
8 mins
February 2026
Bio Spectrum
Decode Age raises Rs 14.48 Cr to advance longevity science and gut microbiome research
Bengaluru-based Decode Age, a longevity science organisation focused on ageing biology, biomarker research and gut microbiome science, has raised Rs 14.48 crore in its Pre Series A funding round led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited.
1 min
February 2026
Bio Spectrum
Havih Envirosciences announces partnership with Andhra Pradesh
Havih Envirosciences, a subsidiary of Maxwell Biosciences, has announced a strategic partnership with the Government of Andhra Pradesh to establish advanced pharmaceutical research and production capabilities in the state.
1 min
February 2026
Bio Spectrum
Biofabri and Bharat Biotech ink technology transfer agreement to advance global access to MTBVAC
Biofabri, a global human vaccine development company that is part of Spain-based Zendal group, and Bharat Biotech International Limited (BBIL) in Hyderabad, a global leader in vaccine innovation and manufacturing, have announced the signing of a Technology Transfer Agreement.
1 min
February 2026
Bio Spectrum
IIT-D and AIIMS develop swallowable microdevice for microbiome study
Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.
1 min
February 2026
Bio Spectrum
Care ADHD expands global operations with first GCC in India
Care ADHD, one of the United Kingdom's fastest growing digital mental health companies and a key partner to the NHS, has announced the opening of its first Global Capability Centre (GCC) in India - Bengaluru.
1 min
February 2026
Listen
Translate
Change font size
